(UroToday.com) Dr. Axel Bex presents his take on the management of metastatic clear cell RCC with systemic therapy, with or without delayed nephrectomy – specifically focusing on the when and how. As the primary author of the SURTIME Study,1 he can speak to the literature with great authority.
(UroToday.com) In this session, Dr. Thomas Powles provides an exploratory analysis of the DANUBE trial, with a focus on the outcomes of durvalumab (Durva) with or without tremelimumab (Treme) stratified by cisplatin eligibility and PD-L1 biomarker status in metastatic urothelial carcinoma (mUC). Dr. De Santis follows this discussion of the data and provides clinical context.
(UroToday.com) Dr. George Thalmann from the University of Bern presented a brief argument for cytoreductive nephrectomy as upfront therapy for metastatic clear cell RCC. His discussion was brief but balanced.
(UroToday.com) The 2021 European Association of Urology (EAU) Annual meeting’s Confederación Americana de Urología lecture was provided by Dr. Alejandro R. Rodriguez discussing the role of TUR in muscle invasive bladder cancer (MIBC). Dr. Rodriguez started by highlighting that bladder cancer is the 10th most commonly diagnosed cancer worldwide with 573,000 new cases and 213,000 deaths. […]
(UroToday.com) Dr. Enrique Grande from Madrid, Spain provided a state-of-the-art lecture at the European Association of Urology (EAU) 2021 annual meeting’s advanced bladder cancer session discussing immunotherapy in the first-line setting for metastatic bladder cancer. Dr. Grande notes that over the last several years, it seems that immunotherapy covers the entire spectrum of first-line treatment of […]
(UroToday.com) The advanced bladder cancer in 2021 session of the European Association of Urology annual meeting included a presentation by Dr. Francois Audenet discussing the role of neoadjuvant immunotherapy in muscle-invasive bladder cancer (MIBC). Cisplatin-based chemotherapy before radical cystectomy is the gold standard for localized MIBC, given that it improves overall survival by 5% and […]
(UroToday.com) Professor James Catto discussed the safe and optimal management of muscle-invasive bladder cancer (MIBC) in the time of COVID-19 pandemic at the European Association of Urology (EAU) 2021 virtual annual meeting’s plenary session on advanced bladder cancer. Based on data from the COVID-19 dashboard at Johns Hopkins University from June 15, 2021, the COVID-19 pandemic […]
(UroToday.com) Dr. William Marston Linehan provides a lecture on the discovery, mechanism, and treatment paradigm for VHL kidney cancer as the invited Society of Urologic Oncology (SUO) lecturer at the European Association of Urology.
(UroToday.com) At the 2021 European Association of Urology annual meeting Game Changing session, Dr. Tom Powles presented results of the KEYNOTE-564 trial evaluating pembrolizumab versus placebo as adjuvant therapy for patients with RCC. In 2018, kidney cancer was responsible for 175,000 deaths worldwide. Nephrectomy is the standard of care treatment for locoregional RCC, however, there is […]
In this EAU TV broadcast, EAU Adjunct Secretary-General and Executive Member Science, Prof. Arnulf Stenzl (DE), led discussions on vital topics on bladder cancer (BCa) and renal cell carcinoma (RCC). Panellists Prof. Dr. Maria Jose Ribal Caparros (ES) and Prof. Joan Palou (ES) offered their insights on BCa. Panellists Prof. Dr. Marc-Oliver Grimm (DE) and […]
